Pneumococcal polysaccharide vaccine in children with chronic renal disease: a prospective study of antibody response and duration.
We studied the antibody response to pneumococcal serotypes 3 and 14 after pneumococcal polysaccharide vaccine was administered to 41 children with renal disease. One month after vaccination, 76% and 61% of patients achieved at least a twofold titer rise to serotypes 3 and 14, respectively; this finding was comparable to historic control values. One year after vaccination, the majority of patients retained protective antibody levels. Achieving a titer > or = 1.0 microgram/ml IgG at 1 month was highly predictive of retaining a protective antibody level > or = 0.15 microgram/ml at 1 year.
Furth
S L
SL
Division of Pediatric Nephrology, Immunology, and Infectious Disease, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21287-2467, USA.
Neu
A M
AM
Case
B
B
Lederman
H M
HM
Steinhoff
M
M
Fivush
B
B
D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood*; D001428:Bacterial Vaccines / Q000008:administration & dosage*; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D007223:Infant; D007676:Kidney Failure, Chronic / Q000276:immunology* / Q000628:therapy; D016030:Kidney Transplantation; D010530:Peritoneal Dialysis; D022242:Pneumococcal Vaccines; D011446:Prospective Studies; D013296:Streptococcus pneumoniae / Q000276:immunology*; D013997:Time Factors
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines